Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 19/20 | 0.45 |
| ▸ | CCND1 | P24385 | 10/20 | 0.45 |
| ▸ | CDK2 | P24941 | 7/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 8/20 | 0.41 |
| ▸ | CDK1 | P06493 | 4/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.41 |
| ▸ | CCND3 | P30281 | 6/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CCNH | P51946 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22650823 | 1.00 | CDK4 (0.45) | CDK4CCND1CDK2CCNA2CCNA1 | |
| SCHEMBL22650417 | 0.93 | CDK4 (0.40) | CDK4CCND1CDK2CCNA2CCNA1 | |
| SCHEMBL22650421 | 0.91 | JAK2 (0.38) | CDK4CCND1CDK2CCNA2CCNA1 | |
| SCHEMBL22650418 | 0.91 | CDK4 (0.39) | CDK4CCND1CDK2CCNA2CCNA1 | |
| SCHEMBL22650594 | 0.90 | CDK4 (0.42) | CDK4CCND1CDK2CCNA2CCNA1 | |
| SCHEMBL22650453 | 0.90 | CDK4 (0.42) | CDK4CCND1CDK2CCNA2CCNA1 | |
| SCHEMBL29491149 | 0.89 | CDK4 (0.38) | CDK4CCND1CDK2CCNA2CCNA1 | |
| SCHEMBL31589956 | 0.89 | CDK4 (0.38) | CDK4CCND1CDK2CCNA2CCNA1 | |
| SCHEMBL22650838 | 0.89 | CDK4 (0.41) | CDK4CCND1CDK2CCNA2CCNA1 | |
| SCHEMBL22650837 | 0.89 | CDK4 (0.41) | CDK4CCND1CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025103447-A1 | SALT AND SOLID FORMS OF A CDK INHIBITOR | GENENTECH, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025102352-A1 | SALT AND SOLID FORMS OF A CDK INHIBITOR | GENENTECH, INC (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20240066031-A1 | CDK INHIBITORS | GENENTECH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2021226140-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2021-11-11 | — | — | WO | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066031-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | CDK4 12/4885CCND1 49/4885CDK2 10/4885 |
| US-20230174512-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | CDK4 12/4885CCND1 49/4885CDK2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.